tetano
Editor, Senior Moderator
Drug Discov Ther
. 2022 Jun 25.
doi: 10.5582/ddt.2022.01036. Online ahead of print.
Efficacy and safety of sotrovimab for vaccinated or unvaccinated patients with mild-to-moderate COVID-19 in the omicron era
Takehiro Izumo[SUP] 1 [/SUP], Nobuyasu Awano[SUP] 1 [/SUP], Naoyuki Kuse[SUP] 1 [/SUP], Keita Sakamoto[SUP] 1 [/SUP], Kohei Takada[SUP] 1 [/SUP], Yutaka Muto[SUP] 1 [/SUP], Kazushi Fujimoto[SUP] 1 [/SUP], Ayae Saiki[SUP] 1 [/SUP], Yu Ito[SUP] 1 [/SUP], Hiroaki Ota[SUP] 1 [/SUP], Minoru Inomata[SUP] 1 [/SUP]
Affiliations
Abstract
Although sotrovimab, one of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies has been shown to be effective in patients with mild-to-moderate coronavirus disease 2019 (COVID-19) with risk factors, their efficacy in mRNA COVID-19 vaccinated patients in omicron era is unknown. To evaluate the effectiveness of sotrovimab clinical data from both COVID-19 vaccinated and unvaccinated patients who were hospitalized and receiving sotrovimab at the Japanese Red Cross Medical Center were compared. The efficacy and adverse events were evaluated. Of the total 60 patients enrolled in this study, 45 had received the mRNA COVID-19 vaccine and 15 were unvaccinated. The clinical progression with low nasal cannula or face mask was not significantly different between groups (occurring in one patient in each group; p = 0.44), with no further progression in both groups. The duration of hospitalization was eight days for both groups (p = 0.90). Two patients in each group experienced adverse events (7%, p = 0.26). The results suggested that the efficacy and safety of sotrovimab against mild-to-moderate COVID-19 with risk factors in the omicron era might not be different regardless of the vaccination status. The results of the present study are encouraging; however, further randomized clinical studies are needed.
Keywords: COVID-19; adverse event; efficacy; neutralizing antibodies; severe acute respiratory syndrome coronavirus 2.
. 2022 Jun 25.
doi: 10.5582/ddt.2022.01036. Online ahead of print.
Efficacy and safety of sotrovimab for vaccinated or unvaccinated patients with mild-to-moderate COVID-19 in the omicron era
Takehiro Izumo[SUP] 1 [/SUP], Nobuyasu Awano[SUP] 1 [/SUP], Naoyuki Kuse[SUP] 1 [/SUP], Keita Sakamoto[SUP] 1 [/SUP], Kohei Takada[SUP] 1 [/SUP], Yutaka Muto[SUP] 1 [/SUP], Kazushi Fujimoto[SUP] 1 [/SUP], Ayae Saiki[SUP] 1 [/SUP], Yu Ito[SUP] 1 [/SUP], Hiroaki Ota[SUP] 1 [/SUP], Minoru Inomata[SUP] 1 [/SUP]
Affiliations
- PMID: 35753770
- DOI: 10.5582/ddt.2022.01036
Abstract
Although sotrovimab, one of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies has been shown to be effective in patients with mild-to-moderate coronavirus disease 2019 (COVID-19) with risk factors, their efficacy in mRNA COVID-19 vaccinated patients in omicron era is unknown. To evaluate the effectiveness of sotrovimab clinical data from both COVID-19 vaccinated and unvaccinated patients who were hospitalized and receiving sotrovimab at the Japanese Red Cross Medical Center were compared. The efficacy and adverse events were evaluated. Of the total 60 patients enrolled in this study, 45 had received the mRNA COVID-19 vaccine and 15 were unvaccinated. The clinical progression with low nasal cannula or face mask was not significantly different between groups (occurring in one patient in each group; p = 0.44), with no further progression in both groups. The duration of hospitalization was eight days for both groups (p = 0.90). Two patients in each group experienced adverse events (7%, p = 0.26). The results suggested that the efficacy and safety of sotrovimab against mild-to-moderate COVID-19 with risk factors in the omicron era might not be different regardless of the vaccination status. The results of the present study are encouraging; however, further randomized clinical studies are needed.
Keywords: COVID-19; adverse event; efficacy; neutralizing antibodies; severe acute respiratory syndrome coronavirus 2.